Roche R1626

Is the polymerase inhibitor R1626 still being tested and how does it's efficacy compare to the protease inhibitors?

[epiphiny]

As far as I know trials on that drug have been discontinued.  However Roche has a new ploymerase inhibitor in development (R7128) and a 2nd generation drug of the same.

It is having great results and human trials trials thus far show that the virus does not develop resistance to it.

I was a Geno 3a null responder to previous SOC of 24 weeks and R7128 took me to UND by Week 4.  I followed up with another 44 weeks of SOC (I was a Phase 1b trial) amd I am now SVR.

[chuckles333]

Wow that's great stuff. I wonder how it works for type 1 people and how close we are to actually gettin approval on this or another, equal PI.

[TeeTom]

I have an invitation to the new R7128 trial and I'm thinkig seriously about participating.

Tommy

[Trish77]

R1626 isn't being continued.  They pulled it partway through the Phase IIb trial due to adverse effects on the immune system (weren't you part of that trial along with me?) and it's dead in the water.

R7128 has shown much more promise.

[DragonSlayer45]

R1728 had a 88% success rate in Phase I trials for treatment Naive geno 1's and 90% for geno 2 and 3 non-responders. You will eb hearing more and more about this drug as the phase II trials get under way. Like Epi said it is a great drug.

Just to elaborate a little more on 1626. It was discontinued due to neutropenia. It was also causing a lot of Gastro problems if I recall. I remember early on R1626 was being pushed over R1728 because it was Roche drug and Teh R7128 was from Pharmasett. After being pulled the R7128 was promoted a little more.It has shown much more promise.

It is still early in the development of this drug and as it goes to later trials with more patients we will get a much clearer picture of how well it will work. It looks very promising so far. I treated as a geno 1 and cleared at week 4. I had a 6 log drop which is impressive. I am guessing you will see a lot of reports coming from the next AASLD conference about it.